GleamWall
中文EN

OLMA Olema Oncology, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1750284 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-57.3%
TTM EPS YoY-36.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-69.8%
ROA-59.5%
ROIC (approx.)-67.3%
Asset turnover—

Leverage & solvency

Liabilities / assets16.4%
Debt / equity0.00x
Current ratio6.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-14.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$157.70M$124.52M
SG&A expense$21.00M$17.74M
Operating income-$178.70M-$142.26M
Pretax income-$162.45M-$129.47M
Income tax$3,000$2,000
Net income-$162.45M-$129.47M
EBITDA-$178.21M-$141.87M
EPS (basic)-1.87-2.20
EPS (diluted)-1.87-2.20
Weighted avg. shares (diluted)87.01M58.74M
Balance sheet
Cash & equivalents$48.30M$139.48M
Short-term investments$457.14M$294.61M
Current assets$515.45M$438.47M
PP&E, net$274,000$746,000
Total assets$533.43M$450.98M
Current liabilities$51.80M$41.76M
Total liabilities$54.87M$42.02M
Shareholders' equity$478.56M$408.96M
Shares outstanding81.38M74.31M
Cash flow statement
Operating cash flow-$146.72M-$104.35M
Capital expenditure—$159,000
Free cash flow—-$104.51M
Investing cash flow-$155.76M-$93.53M
Financing cash flow$211.30M$268.82M
Depreciation & amortization$490,000$393,000
Stock-based compensation$17.59M$22.58M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.